As a privately-held, family-owned pharmaceutical company, Boehringer Ingelheim is focused on science that leads to more health for our patients and their families. In 2014, in cash terms we re-invested 2.7 billion euros (19.9% of sales) back into research and development.
8,100 people work in R&D in Boehringer Ingelheim. During the past decade from 2005 to 2014, we conducted or sponsored 1,414 studies with 115 substances in 95 countries from all regions of the world.
We recently published a brochure with some interesting key facts about our R&D which you can read here